Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant
Open Access
- 25 June 2007
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 40 (4) , 349-354
Abstract
We assessed the outcome of 170 patients with AML in first complete remission, aged 1–47 years (median 29), who had undergone an allogeneic BMT before or after 1990 (n=80 and n=90, respectively); all patients were prepared with cyclophosphamide and TBI; the median follow-up for surviving patients was 13 years. The donor was an HLA-identical sibling in 164 patients. Transplant-related mortality (TRM) was 30% before and 7% after 1990 (PP=0.002); and actuarial 10-year survival was 42 and 79% (PP=0.01), and their median follow-up exceeds 10 years. In conclusion, the overall survival of first remission AML undergoing an allogeneic BMT has almost doubled in the past two decades, despite older age and fewer M3 cases. Improvement has come not only from changes in transplant procedures, but also from effective rescue of patients relapsing after transplant.Keywords
This publication has 21 references indexed in Scilit:
- Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar timeBone Marrow Transplantation, 2005
- Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group reportLeukemia, 2005
- Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United StatesBlood, 2005
- Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remissionCancer, 2005
- Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrowBlood, 2003
- Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trialBlood, 2003
- Chronic graft-versus-host diseaseTransplantation and Cellular Therapy, 2003
- Bone marrow transplantation for paediatric AML in first remission: a systematic review and meta-analysisBone Marrow Transplantation, 2002
- The effect of total body irradiation dose and chronic graft‐versus‐host disease on leukaemic relapse after allogeneic bone marrow transplantationBritish Journal of Haematology, 1989
- CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,STransplantation, 1974